It is being studied in a large phase 3 program before regulators complete their review, which is exactly how a promising drug moves from encouraging early data to something patients can use with confidence
Mannick JB, Schonhoff C, Papeta N, Ghafourifar P, Szibor M, Fang K et al
Hitting a weight-loss plateau may be a normal part of the process, as your body adapts to Wegovy and changes in diet and exercise
15,20 Serious GI AEs, though uncommon, have also been reported with GLP-1 RA therapy, including gastroparesis, intestinal obstruction, pancreatitis, and colonic ischemia